EP Patent

EP1747193A1 — Benzonitrile derivatives to treat musculoskeletal frailty

Assigned to Pfizer Products Inc · Expires 2007-01-31 · 19y expired

What this patent protects

This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to p…

USPTO Abstract

This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, and treat bone fracture and muscle damage in mammals, including humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP1747193A1
Jurisdiction
EP
Classification
—
Expires
2007-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.